The U.S. Food and Drug Administration (FDA) has approved a new medication, Rybelsus (semaglutide) oral tablets, for use in controlling blood sugar in adults with type 2 diabetes, along with diet and exercise. Rybelsus is the first medication in the glucagon-like peptide (GLP-1) receptor class that does not need to be injected to be approved for use in the U.S. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes, and prior to this only injectable forms were approved for use by the FDA. Read more